Alpha Cognition (ACOG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual general meeting scheduled for June 16, 2026, to address key governance and financial matters.
Shareholders will vote on board composition, director elections, and auditor appointment.
Proxy materials and annual report are available online, with voting accessible by mail, phone, or internet.
Voting matters and shareholder proposals
Shareholders will vote to set the number of directors at six, elect six directors, and appoint CBIZ CPAs P.C. as auditor for 2026.
Board recommends voting “FOR” all proposals, including director nominees and auditor appointment.
Shareholder proposals for the 2027 meeting must be submitted by January 15, 2027, for proxy inclusion.
Board of directors and corporate governance
Six director nominees: Michael McFadden, Kenneth Cawkell, Rajeev Bakshi, Phillip Mertz, Bethany Sensenig, and Robert Wills; Len Mertz is not standing for re-election.
Board committees: Audit, Compensation, and Governance/Nomination, all with independent members.
Board emphasizes diversity, independence, and annual performance assessments.
Code of Business Conduct and Ethics and Insider Trading Policy are in place.
Latest events from Alpha Cognition
- Shareholders to vote on board size, director elections, and auditor appointment at June 2026 AGM.ACOG
Proxy filing30 Apr 2026 - ZUNVEYL's rapid growth and LTC focus drive strong revenue and market expansion.ACOG
Corporate presentation30 Mar 2026 - 2025 revenue hit $10.2M with rapid ZUNVEYL adoption and $66M cash supporting 2027 profitability.ACOG
Q4 202526 Mar 2026 - FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update9 Jan 2026 - ZUNVEYL launched in US, $52.8M raised, and strong liquidity supports global expansion.ACOG
Q4 202427 Dec 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing16 Dec 2025 - 2.38M shares registered for resale; ZUNVEYL launch and Asia-Pacific deal drive growth.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL's launch and Asia-Pacific licensing drive growth amid ongoing net losses and Nasdaq listing.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL targets major growth in 2026 with new data, expanded access, and global milestones.ACOG
Fireside Chat3 Dec 2025